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A B S T R A C T
Background
Grade I or low-grade chondrosarcoma (LGCS) is a primary bone tumour with low malignant potential. Historically, it was treated by wide
resection, since accurate pre-operative exclusion of more aggressive cancers can be challenging and under-treatment of a more aggressive
cancer could negatively influence oncological outcomes. Intralesional surgery for LGCS has been advocated more oHen in the literature
over the past few years. The potential advantages of less aggressive treatment are better functional outcome and lower complication rates
although these need to be weighed against the potential for compromising survival outcomes.
Objectives
To assess the benefits and harms of intralesional treatment by curettage compared to wide resection for central low-grade chondrosarcoma
(LGCS) of the long bones.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 4), MEDLINE and Embase up to April 2018. We
extended the search to include trials registries, reference lists of relevant articles and review articles. We also searched 'related articles'
of included studies suggested by PubMed.
Selection criteria
In the absence of prospective randomised controlled trials (RCTs), we included retrospective comparative studies and case series that
evaluated outcome of treatment of central LGCS of the long bones. The primary outcome was recurrence-free survival aHer a minimal
follow-up of 24 months. Secondary outcomes were upgrading of tumour; functional outcome, as assessed by the Musculoskeletal Tumor
Society (MSTS) score; and occurrence of complications.
Data collection and analysis
We used standard methodological procedures recognised by Cochrane. We conducted a systematic literature search using several
databases and contacted corresponding authors, appraised the evidence using the ROBINS-I risk of bias tool and GRADE, and performed
a meta-analysis. If data extraction was not possible, we included studies in a narrative summary.
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Main results
We included 18 studies, although we were only able to extract participant data from 14 studies that included a total of 511 participants;
419 participants were managed by intralesional treatment and 92 underwent a wide resection. We were not able to extract participant
data from four studies, including 270 participants, and so we included them as a narrative summary only. The evidence was at high risk
of performance, detection and reporting bias.
Meta-analysis of data from 238 participants across seven studies demonstrated little or no diKerence in recurrence-free survival aHer
intralesional treatment versus wide resection for central LGCS in the long bones (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.92 to
1.04; very low-certainty evidence). MSTS scores were probably better aHer intralesional surgery (mean score 93%) versus resection (mean
score 78%) with a mean diKerence of 12.69 (95% CI 2.82 to 22.55; P value < 0.001; 3 studies; 72 participants; low-certainty evidence). Major
complications across six studies (203 participants) were lower in cases treated by intralesional treatment (5/125 cases) compared to those
treated by wide resection (18/78 cases), with RR 0.23 (95% CI 0.10 to 0.55; low-certainty evidence). In four people (0.5% of total participants)
a high-grade (grade 2 or dediKerentiated) tumour was found aHer a local recurrence. Two participants were treated with second surgery
with no evidence of disease at their final follow-up and two participants (0.26% of total participants) died due to disease. Kaplan-Meier
analysis of data from 115 individual participants across four studies demonstrated 96% recurrence-free survival aHer a maximum follow-up
of 300 months aHer resection versus 94% recurrence-free survival aHer a maximum follow-up of 251 months aHer intralesional treatment
(P value = 0.58; very low-certainty evidence). Local recurrence or metastases were not reported aHer 41 months in either treatment group.
Authors' conclusions
Only evidence of low- and very low-certainty was available for this review according to the GRADE system. Included studies were all
retrospective in nature and at high risk of selection and attrition bias. Therefore, we could not determine whether wide resection is superior
to intralesional treatment in terms of event-free survival and recurrence rates. However, functional outcome and complication rates are
probably better aHer intralesional surgery compared to wide resection, although this is low-certainty evidence, considering the large eKect
size. Nevertheless, recurrence-free survival was excellent in both groups and a prospective RCT comparing intralesional treatment versus
wide resection may be challenging for both practical and ethical reasons. Future research could instead focus on less invasive treatment
strategies for these tumours by identifying predictors that help to stratify participants for surgical intervention or close observation.
P L A I N   L A N G U A G E   S U M M A R Y
The e4ect of type of surgery for outcome in low-grade chondrosarcoma
Background and review question
Chondrosarcomas are one of the most common types of bone cancer, with varying degrees of severity. These tumours grow from cartilage
forming cells, within the bone, or on the surface of the bone. Low-grade chondrosarcomas (LGCS) are tumours that grow slowly over time
and do not generally metastasize and people do not usually die from this disease. In the late 20th century, the condition was treated by
cutting out large portions of bone surrounding the tumour (wide resection). However, surgeons today more commonly treat these tumours
by scraping the tumour out of the bone (intralesional treatment). In this way, the bone structure is preserved and more extensive surgery
can be avoided. Therefore, people are potentially less disabled and complications can be reduced. This is only appropriate if the survival
outcome of the cancer treatment is not compromised compared to wide resection. We reviewed the evidence for the harms and benefits
of both types of surgery on outcomes in people with LGCS, including tumour recurrence aHer surgery (local recurrence), level of physical
functioning and complications aHer surgery.
Search date
The evidence is current to April 2018.
Study characteristics
We identified 14 studies that were suitable for analysis with a total of 511 participants; 92 were treated by wide resection compared to 419
by intralesional treatment. Age of the participants varied from 13 to 82 years with a mean age of 48 years. Women outnumbered men in
the studies by just over one and a half times, which reflects that LGCS are more common in women. People were followed-up for between
24 to 300 months aHer surgery. In addition, there were four studies including 270 participants, from which we could not extract the exact
data, but were used to confirm the statistical analysis.
Key results
We found that there was little or no diKerence in rates of local recurrence between treatment types. In 94% to 96% of the cases, the tumour
was successfully removed aHer a single operation. In the few cases where disease recurred, a second operation was needed. People with
LGCS probably have better functionality aHer less aggressive intralesional treatment, and complication rates were probably lower compare
to wide surgical resection. Less than 0.3% of all people with LGCS died due to their disease, irrespective of the surgical technique.
Certainty of evidence
Overall certainty of the studies was very low, as all studies only described the results of the treatment in hindsight and none of the studies
randomly selected patients between treatment groups.
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Summary of findings for the main comparison.   Intralesional treatment versus wide resection for central, low-grade (grade I) chondrosarcoma in the
long bones
Intralesional treatment versus wide resection for central, low-grade (grade I) chondrosarcoma in the long bones
Patient or population: people with central, low-grade (grade I) chondrosarcoma in the long bones
Settings: hospital
Intervention: intralesional treatment
Comparison: wide resection
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Wide resection Intralesional treatment
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Recurrence-free survival
(24-300 months' follow-up)
54 per 1000
(19 to 111)
68 per 1000
(34 to 116)
RR 0.98 (0.92
to 1.04)
238
(7 studies)
⊕⊝⊝⊝1
Very low
 
Functional outcome based on
MSTS score (percent)
Scale 0% to 100%, with 100% in-
dicating no functional limitations
The mean MSTS was 78%
and ranged across control
groups from
72.1% to 94.3%
The mean MSTS was 93% and
ranged across intervention
groups from 89.3% to 98.6%
MD 12.7
(2.8 to 22.6)
72
(3 studies)
⊕⊕⊝⊝
Low 2
 
Overall rate of major complica-
tions
(24-300 months' follow-up)
230 per 1000
(150 to 337)
40 per 1000
(13 to 82)
RR 0.23 (0.10
to 0.55)
203
(six studies)
⊕⊕⊝⊝
Low 2
 
Pathological upgrading of tu-
mour
N/A N/A N/A N/A N/A Only 2 cases in
the overall data
had a transition
towards grade II
chondrosarcoma,
based on the narra-
tive reporting of re-
sults
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; MSTS: Musculoskeletal Tumor Society; N/A: not applicable; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate-certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low-certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low-certainty: we are very uncertain about the estimate.
1All included studies were observational studies, which have an initial low level of evidence. We downgraded the evidence level since there were serious risks of bias.
2All included studies were observational studies, which have an initial low level of evidence. We downgraded the evidence since there were serious risks of bias. However, we
upgraded them considering the large eKect.
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B A C K G R O U N D
Description of the condition
Chondrosarcoma is the most common primary malignant bone
tumour aHer osteosarcoma (Bauer 1995; Eriksson 1980; Healey
1986; Rosenthal 1984), and is characterised by a heterogeneous
group of bone malignancies with a cartilaginous origin (Fletcher
2013). Chondrosarcoma constitute 20% to 27% of all primary
bone tumours (Murphey 2003). Reported overall incidence is
1:200,000 to 1:500,000, with men and women being more or
less equally aKected (ESMO 2012; GiuKrida 2009). Incidence is
highest between the 3rd and 7th decade of life (ESMO 2012; Jundt
2008). Chondrosarcoma vary from low-grade, relatively benign to
high-grade or dediKerentiated tumours with very poor survival.
Conventional chondrosarcoma can originate outside the bone
(periosteal or peripheral chondrosarcoma) or within the bone
(central chondrosarcoma); the latter accounts for 75% of all of these
tumours. Tumours can either be intra-compartmental (Enneking
stage IA) or extra-compartmental (Enneking stage IB (Enneking
1986)). Oncological outcome is predominately determined by
histological grading, ranging from I to III, with higher-grade tumours
associated with worse prognosis. Central grade I (low-grade (LG))
chondrosarcoma (LGCS) tumours tend to grow slowly and rarely
metastasize, resulting in an 83% to 89% 10-year survival rate
(Bjornsson 1998; Evans 1977; Fiorenza 2002). Microscopically,
they exhibit a matrix rich in hyaline cartilage (Gelderblom 2008).
The most important clinical symptom is persistent (nocturnal)
pain, although LGCS can be asymptomatic. Treatment of LGCS is
primarily surgical, since these tumours are generally resistant to
radiation or systemic therapy (Eriksson 1980; Lee 1999).
In clinical practice, the treating physician is presented with a
diagnostic dilemma. In a substantial number of cases, it is
diKicult to diKerentiate central LGCS from its benign equivalent,
enchondroma (EeHing 2009; Geirnaerdt 1997; Mirra 1985; Randall
2005). Intermediate- and high-grade chondrosarcoma display
typical signs, such as perilesional oedema and cortical destruction.
Enchondroma can be managed conservatively with observation or
treated with intralesional curettage. Malignant transformation of
a solitary enchondroma is rare. On the other hand, intermediate-
and high-grade chondrosarcoma display a much more aggressive
course, with 10-year survival rates ranging from 53% to 64% and
29% to 38%, respectively, and a higher incidence of local recurrence
and distant metastases (Bjornsson 1998; Fiorenza 2002; GiuKrida
2009). They are treated with 'en bloc' resection (wide resection)
with reconstruction (prosthesis) or amputation, which hampers
joint and limb function. Historically, orthopaedic surgeons tended
to treat LGCS in a similar fashion. More recently, there has been
a tendency to perform intralesional surgery in LGCS by extended
intralesional curettage, preferably with local adjuvant therapy, such
as phenolisation, the use of polymethyl methacrylate (PMMA) and
application of cryotherapy (Donati 2010; Leerapun 2007; Schreuder
1998; Van der Geest 2008; Veth 2005). Some studies suggest
that intralesional surgery could lead to higher local recurrence
rates, which in itself could lead to upgrading towards high-grade
chondrosarcoma (Andreou 2011). LGCS tumours located in the
pelvis and axial skeleton tend to be more aggressive and require
other treatment strategies, oHen similar to higher-grade tumours
(Gelderblom 2008). Therefore, we have described only treatment of
tumours in the long bones in this review.
Description of the intervention
Intralesional surgery in LGCS is carried out by curettage. During
this procedure, the tumour is accessed through a cortical window,
extensive curettage is carried out and oHen supplemented with the
use of a high-speed burr. AHer curettage, local adjuvant therapy
can be applied, either by phenolisation or cryotherapy (see How
the intervention might work). In a large number of cases, bone
cement (PMMA) is used as an additional adjuvant and filler. The
cavity is filled, where necessary, with bone graH or cement; larger
cortical windows can then be refashioned to the bone followed
by routine wound closure. In some cases, prophylactic hardware
(metal pins and plates oHen used to help repair fractured bones)
is used to prevent fracturing. Depending on the site of the tumour,
patients are prohibited from weight bearing six to 12 weeks aHer
surgery. Generally, curettage is indicated if the joint surface is
unaKected, if the lesion is contained in bone or a suKicient bony
architecture remains aHer surgery. The most serious complications
aHer curettage are fracture of the treated site and infection.
How the intervention might work
Extended intralesional curettage removes malignant tumour cells,
but by definition will likely leave some microscopic cells behind.
As a result, local adjuvant therapy is oHen performed. Phenol
has a proven cytotoxic eKect on LGCS cells and is used with
the intention to kill tumour cells that cannot be reached with
the curette (Verdegaal 2012). The strongest evidence exists for
cryotherapy, whereby liquid nitrogen is sprayed or poured into the
bone cavity (Van der Geest 2008). It is thought that local freezing
extends the surgical margin. In some centres, the bone cavity is
filled with PMMA, and it is hypothesised that the heat released
during the exothermic reaction as it sets has an additional cytotoxic
eKect on tumour cells. Given the relatively mild nature of LGCS,
we hypothesise that these measures are suKicient to treat the
disease. The major benefit of curettage compared to wide resection
is improved functional outcome as a result of joint preservation
and the avoidance of large bony resections or ablative surgery.
Although people might be temporarily disabled due to decreased
weight bearing aHer curettage, long-term functionality can oHen
fully be restored.
Why it is important to do this review
LGCS has an overall incidence rate that is relatively low compared to
other types of cancer. To our knowledge, there are no prospective,
randomised controlled trials (RCTs), given the low number of
people aKected. In literature, only small, retrospective studies
have been published comparing intralesional treatment with wide
resection (Aarons 2009; Bauer 1995; Donati 2010; Etchebehere
2005; Leerapun 2007; Schreuder 1998; Van der Geest 2008). This
type of study is oHen subject to a high degree of bias and the
numbers are oHen too small for meaningful statistical analysis.
A systematic review is necessary to search for and summarise
the available evidence. Hickey 2011 performed a meta-analysis on
this specific topic and it showed that intralesional therapy is not
necessarily inferior to wide resection. Since then, several studies
have been published, which justifies an updated overview. This
review will be important, since intralesional treatment may have
significant functional benefits compared to resection. Therefore, if
the intralesional treatment is equally beneficial from a recurrence
and survival point of view, it may be better to perform curettage
instead of wide resection. 
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O B J E C T I V E S
To assess the benefits and harms of intralesional treatment
by curettage compared to wide resection for central low-grade
chondrosarcoma (LGCS) of the long bones.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Since no RCTs or other prospective studies were available,
we included retrospective cohort studies comparing oncologic
outcome of intralesional treatment of LGCS to wide resection in the
long bones (i.e. humerus, radius, ulna, femur, tibia and fibula). In
addition, we included case series with at least 20 participants. We
also included studies examining other types of chondrosarcoma,
from which we retrieved data related to central LGCS. If RCTs
become available in literature, they still will be eligible for inclusion
in future versions of the review.
Types of participants
We included all participants with central LGCS in the long bones. We
did not apply age restrictions.
Types of interventions
We compared intralesional treatment (curettage) with or without
adjuvant (phenol and ethanol, cryosurgery, bone cement or
combinations) to wide resection, including amputation.
Types of outcome measures
We prespecified the following outcomes, which are also included in
the 'Summary of findings' table.
Primary outcomes
Primary outcome was recurrence-free survival (defined as local
recurrence and/or metastases), with a minimum follow-up duration
of two years aHer index surgery.
Secondary outcomes
We considered the following secondary outcomes:
• incidence of pathological upgrading of tumour;• functional outcome based on Musculoskeletal Tumor Society
(MSTS) score, if available. The MSTS score is a well-accepted and
commonly used score to determine function aHer surgery for
bone tumours (Enneking 1993). It includes six categories (pain,
function, emotional acceptance, use of supports, walking ability
and gait), with numerical values from 0 to 5 points; in total 30
points can be reached, oHen also presented as percentage, with
100% equalling 30 points, and 30 points or 100% indicating no
functional limitations;• overall rate of major complications based on the following
adverse events, if available: fracture, infection, re-operation
(due to reasons other than progression of disease) or
thromboembolic events. Grading of adverse events is outside
the scope of this review.
Search methods for identification of studies
Electronic searches
We searched the following databases:
• the Cochrane Central Register of Controlled Trials (CENTRAL;
2018, Issue 4), in the Cochrane Library (Appendix 1);• MEDLINE via Ovid (1946 to April 2018) (Appendix 2);• Embase via Ovid (1980 to 2018, week 17) Appendix 3).
We did not apply language restrictions.
Searching other resources
We extended our search to the reference lists of relevant articles
and review articles, as well as contacting study authors to provide
missing information. We also scanned related articles suggested by
PubMed. In addition, we searched for ongoing trials by scanning
online trials registries, such as Current Controlled Trials (http://
www.isrctn.com), and ClinicalTrials.gov, and searched for oral and
poster abstracts presented in appropriate meetings (e.g. EMSOS,
ISOLS).
Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searching to a reference management database and removed
duplicates. Three review authors (EFD, PCJ, KG) examined the
remaining references independently. We excluded those studies
that clearly did not meet the inclusion criteria. In addition, we
obtained copies of the full text of potentially relevant references.
Three review authors (EFD, PCJ, KG) independently assessed the
eligibility of retrieved publications. We resolved disagreements
by discussion between the three review authors and if necessary
by involving the fourth review author (MS). We documented our
reasons for exclusion. 
Data extraction and management
For included studies, we extracted the following data.
• Author, year of publication and journal citation (including
language)• Country• Setting• Inclusion and exclusion criteria• Study design and methodology• Study population:* total number enrolled;* patient characteristics;* age• Intervention details:* definition/details• Comparison:* definition/details• Risk of bias in study (see below)• Duration of follow-up
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• Outcomes:* for each outcome, we extracted the outcome definition and
unit of measurement (if relevant). For adjusted estimates, we
have recorded variables adjusted for in analyses.• Results:* we extracted the number of participants allocated to each
intervention group, the total number analysed for each
outcome, and the missing participants (if applicable).
We extracted the following information.
• For time-to-event data (survival and disease progression), we
extracted the log of the hazard ratio (log (HR)) and its standard
error from study reports. If these are not reported, we attempted
to estimated the log (HR) and its standard error using the
methods of Parmar 1998.• For dichotomous outcomes we extracted the number of
participants in each treatment arm who experienced the
outcome of interest and the number of participants assessed at
endpoint, in order to estimate an odds ratio (OR).• For continuous outcomes, we extracted the final value and
standard deviation of the outcome of interest and the number
of participants assessed at endpoint in each treatment arm at
the end of follow-up, in order to estimate the mean diKerence
between treatment arms and its standard error.
We noted the time points at which outcomes were collected and
reported.
Three review authors (EFD, PCJ, KG) independently extracted the
data onto a data abstraction form specially designed for the review.
We resolved diKerences between review authors by discussion or
by appeal to a fourth author (MS) if necessary.
Assessment of risk of bias in included studies
We assessed the risk of bias using ROBINS-I, since all studies
were non-randomised, retrospective studies (Sterne 2016). We
achieved consensus on seven domains through which bias might
be introduced into non-randomised studies for interventions
(bias due to confounding, bias in selection of participants into
the study, bias in classification of interventions, bias due to
deviations from intended interventions, bias due to missing data,
bias in measurement of outcomes, and bias in selection of the
reported result). The first two domains, covering confounding and
selection of participants into the study, addressed issues before
the start of the interventions that were compared (“baseline”).
The third domain addressed classification of the interventions
themselves. The other four domains addressed issues arising
aHer the start of interventions: biases due to deviations from
intended interventions, missing data, measurement of outcomes,
and selection of the reported result (Sterne 2016).
Important confounders of interest in this Cochrane Review include
the following.
• Tumour stage (Enneking 1A or 1B)• Surgical techniques and local adjuvants• Pathological diagnosis• Time period of treatment
Three review authors (EFD, PCJ, KG) applied the 'Risk of bias' tool
independently and resolved diKerences by discussion or by appeal
to a fourth review author (MS). We summarised results in both a
'Risk of bias' graph and a 'Risk of bias' summary. We interpreted
results of meta-analyses in light of the findings with respect to
risk of bias. Each of the seven domains of bias contains signalling
questions to facilitate judgements of risk of bias. The full signalling
question and response framework for each outcome is provided
in Sterne 2016. Following completion of the signalling questions,
we determined a 'Risk of bias’ judgement for each domain and
obtained an overall 'Risk of bias’ judgement for each outcome and
result assessed. Overall risk of bias has four categories ranging from
low risk of bias (the study is at low risk of bias across all domains)
to critical risk of bias (the study is at critical risk of bias in at least
one domain). If there was insuKicient information to assess the risk
of bias in one or more key domains, but there was no indication
that there was any critical or serious risk of bias in any of the other
domains, then we have designated the overall classification as 'no
information'.
Measures of treatment e4ect
We used the following measures of the eKect of treatment.
• We had hoped to use hazard ratios (HRs) for time-to-event data
but the data only allowed us to compute the risk ratio (RR) and
OR.• For dichotomous outcomes, we used the RR.• For continuous outcomes, we used the mean diKerence (MD)
between treatment arms.
Unit of analysis issues
No cluster-RCT or cross-over RCTs were available for inclusion. We
could not identify multiple groups within the studies presented.
Dealing with missing data
We did not impute missing outcome data for the primary outcome.
If data were missing we contacted study authors to request data
only on the outcomes for the participants they had assessed.
Assessment of heterogeneity
We assessed heterogeneity between studies by visual inspection
of forest plots, by estimation of the percentage heterogeneity
between studies that could not be ascribed to sampling variation
(Higgins 2003), by a formal statistical test of the significance
of the heterogeneity (Deeks 2001). If there had been evidence
of substantial heterogeneity, we would have investigated and
reported the possible reasons for this.
Assessment of reporting biases
Reporting bias was assessed as part of the 'Risk of bias' tool (Sterne
2016).
Data synthesis
In case of clinically and statistically homogeneous studies,
we pooled their results in meta-analyses using the Cochrane
Collaboration's statistical soHware, Review Manager 2014.
Although there were no signs of significant heterogeneity, due
to subtle diKerences in diagnostics and treatments, we used
a random-eKects model. If individual time-to-event data were
present, we extracted them to compute the Kaplan-Meyer curve
of recurrence-free survival. For time-to-event data we were only
able to compute RRs and ORs. For dichotomous outcomes, we
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calculated the RR for each study and pooled them. For continuous
outcomes, we pooled the MDs between the treatment arms at the
end of follow-up.
Subgroup analysis and investigation of heterogeneity
We did not conduct subgroup analysis.
Sensitivity analysis
We did not perform sensitivity analyses excluding studies at high
risk of bias, since all studies were at high risk of bias.
Main outcomes of 'Summary of findings' table for assessing the
certainty of the evidence
We presented the overall certainty of the evidence for each main
outcome according to the GRADE approach, which takes into
account issues not only related to internal validity (risk of bias,
inconsistency, imprecision, publication bias) but also to external
validity, such as directness of results (Langendam 2013). We created
Summary of findings for the main comparison based on the
methods described the Cochrane Handbook for Systematic Reviews
of Interventions (Schünemann 2017), and using GRADEpro GDT
(GRADEpro GDT 2015). We used the GRADE checklist and GRADE
Working Group certainty of evidence definitions (Meader 2014). We
downgraded the evidence from 'high' certainty by one level for
serious (or by two for very serious) concerns for each limitation.
• High-certainty: we are very confident that the true eKect lies
close to that of the estimate of the eKect.• Moderate-certainty: we are moderately confident in the eKect
estimate: the true eKect is likely to be close to the estimate of the
eKect, but there is a possibility that it is substantially diKerent.
• Low-certainty: our confidence in the eKect estimate is limited:
the true eKect may be substantially diKerent from the estimate
of the eKect.• Very low-certainty: we have very little confidence in the eKect
estimate: The true eKect is likely to be substantially diKerent
from the estimate of eKect.
The main outcomes were recurrence-free survival, MSTS scores and
rates of major complications.
R E S U L T S
Description of studies
Results of the search
No studies were identified through CENTRAL. The MEDLINE and
Embase searches identified 331 and 519 records respectively, and
handsearching yielded two additional studies. AHer removal of
duplicate studies and title and abstract screening, we included a
total of 32 studies for potential eligibility, (see Figure 1 for flow-
chart (Moher 2009)). We fully reviewed the full texts of all 32 selected
papers for eligibility and we excluded 14 studies because their
sample size was too small, or they had not documented data
concerning recurrence-free survival for LGCS in the long bones (see
Excluded studies). We included a total of 18 studies in this review.
Of these, seven studies were suitable for meta-analysis; details
of these studies can be found in the Characteristics of included
studies section. In addition, we used participant data from seven
case series in the narrative summary or to assess recurrence-free
survival and included four studies for qualitative analysis only,
since we could not extract participant data, and are described in the
Characteristics of included studies section.
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Figure 1.   Study flow diagram
 
Included studies
Design of the studies
There were no RCTs or quasi-RCTs available. Aarons 2009, Bauer
1995, Chen 2017, Campanacci 2013, Donati 2010, Etchebehere
2005 and Gunay 2013 were retrospective studies comparing
intralesional treatment versus wide resection. The remaining 11
studies were retrospective case series or cohort series available for
qualitative analysis on recurrence-free survival (Di Giorgio 2011;
Dierselhuis 2016; Funovics 2010; Hanna 2009; Kim 2015; Kim 2018;
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Leerapun 2007; Mermerkaya 2014; Mohler 2010; Van der Geest 2008;
Verdegaal 2012). The case series included only participants that
were treated by intralesional surgery and were not controlled by
wide resection.
Sample sizes
In total, the comparative studies included 238 participants (sample
sizes from 8 to 85), 146 managed by intralesional management
and 92 by wide resection. The case series included in the narrative
summary studied 249 participants (sample sizes from 21 to 108),
managed by intralesional treatment. The four studies that were
only included in the qualitative analysis included 270 participants
(sample sizes from 55 to 85).
Participants
Age, gender and follow-up
The mean age of the participants was 45.8 years (range 13 to 80),
in participants included in the meta-analysis, and 51.5 (range 18 to
82), in the cases series. A slight female preponderance was present
in the cohort included in the meta-analysis, with a male to female
ratio of 1:1.3. Mean follow-up was 85.2 months (range 24 to 300), in
the studies included in the meta-analysis and 56.8 months (range
26 to 134), in the case series.
Disease severity
Aarons 2009, Chen 2017, Dierselhuis 2016, Hanna 2009, Kim 2015,
Kim 2018 and Mermerkaya 2014 included only Enneking stage IA
tumours. Bauer 1995, Campanacci 2013, Etchebehere 2005 and
Gunay 2013 included both Enneking stage IA and IB. It is unclear
whether Di Giorgio 2011, Donati 2010 and Mohler 2010 included
only stage IA or both tumour stages.
Excluded studies
We excluded the following eight studies: Ahlmann 2007, Okada
2009, Ozaki 1996, Puri 2009, Schreuder 1998 and Souna 2010 did
not include a suKicient number of participants; and Errani 2017 and
Lee 1999 studied a heterogeneous group of LGCS (either primary,
secondary, in the axial skeleton or in extremities). These studies
did not document the outcome of participants with primary LGCS
in the long bones, and we could not, therefore, include them
in the meta-analysis or narrative summary, since the majority of
study participants did not meet our inclusion criteria. Full exclusion
details can be found in Characteristics of excluded studies.
Andreou 2011, Angelini 2012, de Camargo 2010, Ma 2009, MeHah
2013 and Streitbuerger 2009 contained valuable data on the
outcome of treatment of LGCS, however we could not extract
the exact data from the studies due to their heterogeneous
nature. In all cases we attempted to contact the study authors for
individual participant data, which could not be obtained. We have
summarised these studies under Characteristics of studies awaiting
classification.
Risk of bias in included studies
Overall, there was a high risk of bias in the included comparative
studies (see Figure 2 and Figure 3). This bias was mainly caused
by confounding bias, in selection of participants (selection bias)
and in classification of interventions. In these studies, identification
of confounding variables was absent and thus we did not
perform analysis of confounding. Selection bias was apparent
in these retrospective studies, as there was no control of the
inclusion of participants. In addition, insight into the choice of
intervention for a specific participant is very probably related to
participant characteristics, such as aggressiveness, or staging of the
tumours, or both. About half of the studies suKered from missing
data (attrition bias). Measurement of outcomes and selection of
reported results (reporting bias) are less likely to be problematic.
There were also suspected other biases because groups were
not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
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Figure 2.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study
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Figure 3.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
 
Bias due to confounding
Risk of bias due to confounding was high in all studies
Bias in selection of participants into the study
Risk of bias in selection of participants into the study was high in all
studies, except for Etchebehere 2005, which we regarded as unclear
risk.
Bias in classification of interventions
Risk of bias in classification of interventions was high in all studies,
except for Funovics 2010, Van der Geest 2008, Verdegaal 2012, which
were regarded as unclear.
Bias due to deviations from intended intervention
Risk of bias due to deviations from intended intervention was
unclear in all studies
Bias due to missing data
In Aarons 2009, Campanacci 2013 and Chen 2017 there was a low
risk of bias due to missing data. There was a high risk of bias in
Bauer 1995, Etchebehere 2005, and Gunay 2013, and an unclear risk
in Donati 2010.
Bias in measurement of outcomes
Risk of bias in measurement of outcomes was low in all studies,
except for Gunay 2013, which we regarded as unclear risk.
Bias in selection of the reported result
Risk of bias in selection of the reported result was low in Aarons
2009, Campanacci 2013, Chen 2017, Donati 2010 and Etchebehere
2005. High risk of bias was expected in Bauer 1995 and Gunay 2013.
Other bias
In all studies there was a risk of bias as groups were not controlled
for experience of the surgeon, and pre-operative functioning level
of the participants. Nevertheless, all studies took place in tertiary
referral hospitals, where we would expect to find an experienced
operating team.
From risk of bias to certainty of evidence
As all outcomes were based on solely observational studies, the
entry point of the outcomes on a certainty-of-evidence level was
low. Further adjustment of the level of certainty of the evidence is
indicated under EKects of interventions section.
E4ects of interventions
See: Summary of findings for the main comparison Intralesional
treatment versus wide resection for central, low-grade (grade I)
chondrosarcoma in the long bones
Quantitative synthesis: controlled studies included in meta-
analysis
Data from the comparative studies are represented in the Summary
of findings for the main comparison.
Recurrence-free survival
There is very low-certainty evidence (observational studies with a
serious risk of bias) from seven studies (n = 238) that the diKerence
in recurrence-free survival aHer intralesional treatment versus wide
resection for central LGCS in the long bones is not statistically
significant (RR 0.98; 95% CI 0.92 to 1.04; Analysis 1.1; Figure 4).
There was one participant with upgrading of tumour to grade II,
treated with second surgery with no evidence of disease at known
follow-up (Campanacci 2013). As is shown in Figure 4, I2 = 0%, which
implies that there was no evidence of substantial heterogeneity.
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Figure 4.   Forest plot of comparison 1. Comparative studies, outcome 1.1 recurrence-free survival. Event =
recurrence-free survival
 
Functional outcome
There is low-certainty evidence (observational studies with a
serious risk of bias) from three studies (n = 72) that intralesional
surgery is more eKective in acquiring higher MSTS scores than wide
resection (93% versus 78%, respectively; mean diKerence 12.7; 95%
CI 2.8 to 22.6; P < 0.001; Analysis 1.2; Figure 5). We upgraded the
certainty of evidence from very low to low due to the large eKect.
 
Figure 5.   Forest plot of comparison 1. Comparative studies, outcome 1.2 function by MSTS score
 
Major complications
There is low-certainty evidence (observational studies with a
serious risk of bias) from six studies (n = 203) that intralesional
surgery is more eKective in preventing major complications (5/125)
as compared to wide resection (18/78 cases), with RR 0.23 (95% CI
0.10 to 0.55; Analysis 1.3; Figure 6). We upgraded the certainty of
evidence from very low to low due to the large eKect.
 
Figure 6.   Forest plot of comparison 1. Comparative studies, outcome 1.3 complications. Event = major complication
(e.g. fracture, infection)
 
Narrative summary of case series and studies not included in
meta-analysis
Several studies were case series describing one type of treatment,
or we were unable to extract data from them, so we have included
these studies in the narrative summary only because we could not
include them in the meta-analysis.
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Recurrence-free survival (case series, exact participant data
available)
Recurrence-free survival in the case series in which curettage with
adjuvant was applied, was 96% in Di Giorgio 2011 (23 participants),
95% in Dierselhuis 2016 (108 participants), 95% in Hanna 2009 (39
participants), 100% in Kim 2015 (36 participants), 100% in Kim
2018 (24 participants), 100% in Mermerkaya 2014 (21 participants)
and 91% in Mohler 2010 (22 participants), all in line with the
meta-analysis. In Di Giorgio 2011, there was one participant with
upgrading of tumour to grade II, treated with second surgery with
no evidence of disease at known follow-up. We were unable to
synthesise data from these case series into the meta-analysis due
to lack of control group.
Recurrence-free survival (comparative studies or case series,
exact participant data not available)
Funovics 2010 treated 70 participants with LGCS in the trunk
and extremities. Local recurrence occurred in eight participants
(11.4%), all in the intralesional (17.9%), or marginal (14.3%),
and none in the wide resection group. Recurrence-free survival
was significantly better for participants with extremity lesions
compared to truncal lesions with 94.0% and 91.5% at 24 and 48
months, in line with the meta-analysis. Leerapun 2007 analysed 70
participants with LGCS in the long bones that were treated either by
marginal or wide resection, or by intralesional treatment. Overall
five-year recurrence-free survival was 89%, which was not in line
with the meta-analysis. There was no diKerence in survival between
intralesional excision (79%) and wide resection (91%) respectively,
in line with the meta-analysis. Overall mortality was 2.9%, with
one participant aHer development of a dediKerentiated out of
local recurrence and one aHer local recurrence with upgrading to
grade II tumour aHer resection, which is not in line with the meta-
analysis. Verdegaal 2012 analysed 85 participants with LGCS in the
long bones, treated by intralesional surgery with local adjuvant.
AHer mean follow-up of 6.8 years there was a 94% recurrence-free
survival, in line with the meta-analysis. No metastases, upgrading
of tumour or death due to disease was observed, also in line with
the meta-analysis. Van der Geest 2008 treated 130 tumours in 123
participants with curettage and cryotherapy. They included active
enchondromas (n = 18), aggressive enchondromas (n = 57) and
LGCS (n = 55). During follow-up two participants (2%) suKered from
a local recurrence, both were participants with an enchondroma.
None of the participants with LGCS had a local recurrence, or other
oncologic events, in line with the meta-analysis.
Functional outcome (case series, exact participant data
available)
The following studies documented MSTS scores: Di Giorgio 2011
(mean 90%); Hanna 2009 (mean 94%); Kim 2018 (mean 92%);
Mermerkaya 2014 (mean 95%); and Mohler 2010 (mean 91%). These
results were all in line with the meta-analysis.
Major complications (case series, exact participant data
available)
In Di Giorgio 2011, major complications occurred in 13% of
participants; in Dierselhuis 2016, 15%; and in Kim 2015, 17%; these
results were not in line with the meta-analysis. In Kim 2018, no
complications occurred, in Mermerkaya 2014 and Mohler 2010, 5%
of participants suKered from complications, in line with the meta-
analysis.
Major complications (comparative studies or case series, exact
participant data not available)
Complications occurred in 13% of participants in Funovics 2010,
with 5% in the intralesional group versus 29% in the wide resection
group (P value = 0.002), in line with the meta-analysis. In Verdegaal
2012, one participant (1.2%) suKered from a wound infection
and two participants (2.4%) from a femoral fracture, in line with
the meta-analysis. Verdegaal 2012 re-operated on 11 participants
for suspected recurrences, which were confirmed in five cases.
Eighteen post-operative fractures occurred (14%) in the series from
Van der Geest 2008, which was not in line with meta-analysis.
Individual participant data
Kaplan-Meier analysis of the data from 115 individual participants
(wide resection n = 51, intralesional surgery n = 64), across
four studies (Aarons 2009, Bauer 1995, Donati 2010, Etchebehere
2005), demonstrates 96% recurrence-free survival aHer a maximum
follow-up of 300 months aHer resection versus 94% recurrence-
free survival aHer a maximum follow-up of 251 months aHer
intralesional treatment (P value = 0.58; Figure 7). Local recurrence
or metastases were not reported aHer 41 months in either
treatment group.
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Figure 7.   Kaplan Meyer survival curve of recurrence-free survival of participants with LGCS in the long bones. P =
0.58
 
D I S C U S S I O N
The objective of this systematic review was to compare the
outcome of intralesional surgery versus wide resection for central
LGCS of the long bones. The primary endpoint was recurrence-
free survival with a minimal follow-up of two years aHer index
surgery. Secondary endpoints were incidence of tumour upgrading,
functional outcome (as measured by the MSTS score) and the
overall rate of complications.
Summary of main results
The review found little or no diKerence in recurrence-free survival
aHer intralesional surgery as compared to wide resection in LGCS
of the long bones (Analysis 1.1). Intralesional surgery probably
led to better functional outcome (Analysis 1.2), and demonstrated
lower major complication rates (Analysis 1.3). Taking into account
all limitations from the included studies, we graded the evidence
for these outcomes as very low and low certainty. With respect to
the qualitative analysis, all but one study (Leerapun 2007), were
in line with the meta-analysis concerning recurrence-free survival.
In four case series (Di Giorgio 2011; Dierselhuis 2016; Kim 2015;
Van der Geest 2008), there were a relatively high number of post-
operative fractures, either due to non-aggressive plating or use of
cryosurgery.
Overall completeness and applicability of evidence
There is very low-certainty evidence on the treatment of LGCS in
the long bones based on the retrospective comparative studies and
case series. However, the participants included in the studies and
the applied techniques represent the known patient population
and are therefore relevant to current practice. All the studies
documented the event of a local recurrence or other signs of
disease. All local recurrences occurred within 41 months aHer
index surgery; 63% of the participants had a minimal follow-up
of five years. Aarons 2009, Chen 2017, Di Giorgio 2011, Donati
2010, Hanna 2009, Mermerkaya 2014 and Mohler 2010 measured
functional outcome in 175/487 (36%) of the participants. The
studies did not describe the time-point at which they assessed
functional outcome, however we hypothesised that the studies
had documented it at the final stage of follow-up. The occurrence
of major complications was documented in most participants
(413/487; 85%), except in Bauer 1995 and Hanna 2009. However,
several studies did not document loss to follow-up (Donati 2010;
Etchebehere 2005; Gunay 2013; Hanna 2009; Kim 2015; Mermerkaya
2014; Mohler 2010). This might have biased outcomes, since
participants that died due to disease or were referred to other
centres may not have been included.
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Quality of the evidence
Certainty (quality) of the evidence was very low according to GRADE
(Summary of findings for the main comparison), and 'Risk of bias'
assessment, since only retrospective comparative studies and case
series were available for inclusion in this review. Observational
studies initially have a low level of evidence certainty, and
consequently, we downgraded the included studies considering
the high risk of biases. For the secondary outcomes (functional
outcome and complications), there was a large eKect, which
allowed us to upgrade the level of evidence by one level. To date,
there are no prospective studies available in literature nor any
RCTs. However, we were able to extract individual data from 115
participants, which enabled as to compute a Kaplan Meyer curve
of recurrence-free survival. In this way, progression of disease for
LGCS could be reconstructed in detail. It is not to be expected
that the level of evidence will increase in studies to come, unless
prospective cohort studies evaluating a treatment strategy are
designed.
Potential biases in the review process
The oncological outcomes presented in many of the comparative
studies should be interpreted with caution, as these studies
are highly susceptible to selection bias, since people treated
by intralesional curettage tended to have less aggressive LGCS
(Aarons 2009; Bauer 1995; Donati 2010; Gunay 2013). Moreover,
case series only reported the outcome of intralesional surgery,
while people with more aggressive tumours radiologically were
managed with wide resection, and thus excluded. Furthermore,
case series concerning intralesional treatment might be subject to
publication bias favouring the series in which participants do well.
An important distinction should also be highlighted with respect to
Enneking stage IA and IB disease. Cortical breakthrough may be a
sign of increased local aggressiveness; the implication in terms of
treatment modality is unclear and raises the question as to whether
these lesions should be treated along the same lines or not. Only
Bauer 1995 and Gunay 2013 reported treatment of Enneking stage
IB explicitly. Bauer 1995 treated four cases with stage IB, three by
intralesional treatment and one by wide resection. None of these
tumours developed a local recurrence. Gunay 2013 treated all 11
cases with stage IB LGCS by wide resection. Of these, two (18%)
developed a local recurrence. This rate is higher than that reported
by other studies in this review, but is nevertheless comparable to
their overall rate of local recurrence (6/30 participants (20%)).
Agreements and disagreements with other studies or
reviews
We are uncertain whether intralesional surgery improves
recurrence-free survival, functional outcome and complication
rates compared to wide resection, as we assessed the certainty of
the evidence as being very low. Nevertheless, this analysis seems
in line with the previously published meta-analysis of Hickey 2011.
It should be noted that one study that we included in the narrative
summary observed death due to disease (Leerapun 2007), one case
aHer intralesional treatment and one case aHer wide resection.
This is in conflict with the results from all the other included
studies. We are not able to solve the controversy whether local
recurrence precedes upgrading of tumour, or that local recurrence
is the consequence of a underdiagnosed higher-grade tumour.
Although speculative, it is not unthinkable that the absence of
(high-certainty) magnetic resonance imaging in the 1970's and
1980's could have led to a higher rate of underdiagnosed tumours.
This is supported by the fact that death due to disease is no longer
seen in studies that are published aHer 2010, although this could
also be subject to publication bias.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There was very limited and very low-certainty evidence on how to
treat central low-grade chondrosarcoma (LGCS) of the long bones.
We only found retrospective comparative studies or case series,
which are greatly biased by patient selection. Based on these data,
there is evidence of very low certainty that recurrence-free survival
is equal between intralesional treatment and wide resection. There
is evidence of very low certainty that intralesional surgery increases
functional outcome as reported by Musculoskeletal Tumor Society
(MSTS) scores. The included studies described many forms of
adjuvants, such as phenolisation, the use of nitrogen, anhydrous
alcohol and the application of polymethyl methacrylate (PMMA).
Details regarding the use of these adjuvants were lacking in most
studies and so we could not assess them.
Among the papers included in the meta-analysis and Kaplan Meyer
calculation, there were no local recurrences aHer 41 months. Only
three cases have been reported in modern literature where local
recurrence occurred beyond five years for this tumour subtype.
Verdegaal 2012 and MeHah 2013 reported cases of local recurrence
at 64 months, 91 months and 67 months respectively.
Implications for research
Considering the low incidence of this disease and the oncologic
sequelae, such as local recurrence, future research is best
performed in a multinational setting. The current level of evidence
supporting intralesional treatment of LGCS is of very low certainty.
Nevertheless, in our opinion a prospective randomised controlled
trial comparing intralesional treatment versus wide resection
may be unwarranted for both practical and ethical reasons. As
this review has demonstrated, local recurrence aHer intralesional
treatment occurs in approximately 5% of people only, with no
demonstrable negative eKect on patient survival. Future research
should, perhaps, instead focus on less invasive treatment strategies
for these tumours by identifying predictors that help to stratify
people for surgical intervention or close observation. During
the development of this review, the World Health Organization
(Fletcher 2013), renamed LGCS as an atypical cartilaginous tumour
(ACT). By definition, they are now tumours of borderline or low
malignant potential. Although outside the scope of this review,
considering the very low number of reported local recurrences and
the fact the metastasis is so rare, there may even be a case for
observation of smaller, less active lesions, especially those without
cortical scalloping.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Study design: retrospective cohort study
Country: USA
Setting: single-centre; hospital; 1989-2005
Participants Total participants: n = 33 (resection n = 16; intralesional n = 17)
Loss to follow-up: 3 participants died to unrelated cause
Age mean (range): resection 48 (21-80); intralesional 51 (14-76)
Sex M:F: 12:21
Inclusion criteria: grade I CS of the long bones of the appendicular skeleton, treated operatively
Exclusion criteria: local recurrent disease or metastasis at presentation; extracompartmental (stage
IB) disease
Follow-up months (range): 24-203
Interventions Resection: resection with variable reconstructions: intercalary allograft, osteoarticular allograft, endo-
prosthesis, allograft-endoprosthesis composites
Intralesional: 3 cycles of extended curetting; variable adjuvants (phenol, liquid nitrogen, PMMA, hy-
drogen peroxide, none)
Selected prophylactic internal fixation
Outcomes Primary outcome: local recurrence
Secondary outcome: MSTS scores; complications
Notes Individual participant data. Extra data (1 participant) were obtained from the study authors
Risk of bias
Bias Authors' judgement Support for judgement
Aarons 2009 
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Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This is a retrospective study comparing 2 surgical techniques, the more ag-
gressive technique might have been used for the more aggressive featured tu-
mours. However, since only Enneking Grade IA tumours are included, it can be
expected that baseline tumour characteristics are probably alike.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk There were no missing data concerning the pre-described outcomes.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Aarons 2009  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: Sweden
Setting: single-centre; hospital; 1967-1991
Participants Total participants: original article n = 40. After exclusion n = 35 (resection n = 13; intralesional n = 22)
Loss to follow-up: 2 participants moved abroad; 4 participants died due to unrelated causes
Age range: 14-70
Sex M:F: 18:17
Inclusion criteria: histologically proven grade I CS, tumours in the extremities
Exclusion criteria: tumours in the hand
Follow-up months (range): 24-300
Interventions Resection: resection with or without reconstructions: intercalary allograft, osteoarticular allograft, en-
doprosthesis
Intralesional: intralesional curettage, filled either with bone chips or PMMA
Outcomes Local recurrence and metastases
Notes Individual participant data. Five participants were excluded from this analysis since they did not meet
the inclusion criteria for this review: 3 participants were treated conservatively, 1 had a tumour in the
foot and 1 in the patella
Bauer 1995 
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Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This is a retrospective study comparing 2 surgical techniques, with both En-
neking grade IA and IB tumours. Intralesional treatment of grade IB tumours
could lead to a higher local recurrence rate, although this is not reported. Par-
ticipants are included over multiple decades (1960s to present), which does
raise some concern over the ability to achieve a correct histopathology diag-
nosis (i.e. distinguishing these lesions from enchondroma and higher-grade
CS) given imaging technology limitations.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Although the given individual participant data are complete, local recurrence
might be underreported considering the available imaging techniques.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
High risk Outcome parameters were not well pre-described.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Bauer 1995  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: Italy
Setting: single-centre; hospital; 1994-2010
Participants Total participants: n = 85 (resection n = 21; intralesional n = 64)
Loss to follow-up: none
Age mean (range): 50 (20-76)
Sex M:F: 24:61
Inclusion criteria: participants treated for central grade 1 CS of long bones
Exclusion criteria: insufficient follow-up (< 24 months)
Follow-up months (range): 24-206
Interventions Resection: resection with variable reconstructions: intercalary allograft, osteoarticular allograft, endo-
prosthesis, allograft-endoprosthesis composites
Campanacci 2013 
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Intralesional: curettage with phenol/ethanol as local adjuvant in 69% of cases. Filling of the cavity was
done with allogenic bone chips in 60 cases, PMMA in 3 cases and bone graH substitute in 1 case.
Outcomes Primary outcome: local recurrence, metastases and/or upgrading of tumour
Secondary outcome: complications
Notes Aggregated data. We tried to contact the study author to obtain individual participant data, but we
were unsuccessful.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This is a retrospective study where tumours with more aggressive radiologi-
cal features were treated by wide resection. Case selection may therefore in-
fluence the estimate of the treatment effect in favour of intralesional surgery
since only the less aggressive cases were treated by curettage.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk There were no missing data concerning the pre-described outcomes.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Campanacci 2013  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: Taiwan
Setting: single-centre; hospital; 1998-2013
Participants Total participants: original article n = 11. After exclusion n = 8 (resection n = 3; intralesional n = 5)
Loss to follow-up: not clearly mentioned; 1 participant died due to unrelated cause
Age range: 20-71
Sex M:F: unknown
Inclusion criteria: stage IA CS
Chen 2017 
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Exclusion criteria: locally recurrent or metastatic disease at present; participants diagnosed with so-
called borderline, grade I-II CS from preoperative biopsy; secondary CS; extraosseous lesions; stage IB
CS
Follow-up months (range): 24-300
Interventions Resection: wide excision, reconstruction with arthroplasty or extracorporeal irradiated bone
Intralesional: curettage, adjuvant phenolisation or cryotherapy. Allograft
Outcomes Local recurrence, progression of disease, complications, MSTS scores
Notes Individual participant data. 3 participants with acetabular lesions were excluded for analyses.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk Tumours were all stage IA tumours, and tumour size was not significantly dif-
ferent between groups. However, the latter could be a result of the small sam-
ple size. Mean tumour size was 6.9 ± 5.1 cm and 12.5 ± 3.1 cm in the intralesion-
al group and resection group respectively, which suggests that the larger tu-
mours were treated more aggressively. Moreover, participants in the resec-
tion group were significantly older (34.0 ± 13.3 years versus 61.0 ± 7.7 years P <
0.001), which might overestimate the risk of complications and underestimate
functional outcome.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented
Bias due to missing data Low risk There were no missing data concerning the pre-described outcomes
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Chen 2017  (Continued)
 
 
Methods Study design: case series
Country: Italy
Setting: single-centre; hospital; 1997-2008
Participants Total participants: n = 23
Di Giorgio 2011 
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Loss to follow-up: not mentioned
Age mean (range): 45 (29-71)
Sex M:F: 11:12
Inclusion criteria: intramedullary grade I CS of a long bone, with diagnosis based on clinical, radiologi-
cal and histological findings
Exclusion criteria: not mentioned
Follow-up months (range): 30-132
Interventions Intralesional: curettage, adjuvant phenol/ethanol and filling with either PMMA or bone chips
Outcomes Primary outcome: local recurrence
Secondary outcome: MSTS scores; complications
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This is a retrospective case series that only included cases treated intralesion-
ally. Dimensions and stage of tumour are unknown, so there is a potential that
mainly small, stage IA tumours were included and that larger, more aggressive
tumours were treated by wide resection and excluded from the study.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk There were no missing data concerning the pre-described outcomes.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Di Giorgio 2011  (Continued)
 
 
Methods Study design: case series
Country: the Netherlands
Setting: single-centre; hospital; 2006-2012
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Participants Total participants: n = 112
Loss to follow-up: 4
Age mean (range): 54 (25-82)
Sex M:F: 1:1.8
Inclusion criteria: intramedullary LGCS of a long bone, with diagnosis based on clinical, radiological
and histological findings
Exclusion criteria: previous treatment in other hospital
Follow-up months (range): 24.3-97.5
Interventions Intralesional: curettage, adjuvant phenol/ethanol and filling with either PMMA, bone chips or synthet-
ic bone (Vitoss® or PRO-DENSE®)
Outcomes Primary outcome: local recurrence or presence of residual tumour after surgery
Secondary outcome: death from disease, metastasis, tumour upgrading or dedifferentiation, and type
and rate of complications
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This is a case series that only describes one technique, which could be subject
to selection bias. However, all types of CS1 in the long bones, with varying di-
mension up to 100 cm3 were included. However, stage IB tumours were not in-
cluded and probably treated more aggressively.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk There were no missing data concerning the pre-described outcomes.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Dierselhuis 2016  (Continued)
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Country: Italy
Setting: single-centre; hospital; 1977-1998
Participants Total participants: n = 31 (resection n = 16; intralesional n = 15)
Loss to follow-up: not mentioned
Age mean (range): 35 (13-67)
Sex M:F: 13:18
Inclusion criteria: grade I CS in the long bones
Exclusion criteria: presence of Ollier's disease, inadequate radiographic documentation, < 60 months'
follow-up, tumour in short bones or consultation only
Follow-up months (range): 66-296
Interventions Resection: resection with variable reconstructions: intercalary allograft, osteoarticular allograft, or en-
doprosthesis
Intralesional: curettage, some with local adjuvant: phenol/ethanol or liquid nitrogen. Filling with PM-
MA, allograft or autograft. 3 participants had hardware stabilisation
Outcomes Primary outcome: local recurrence
Secondary outcome: MSTS scores; complications
Notes Individual participant data
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This is a retrospective study comparing intralesional surgery versus wide re-
section, in which participants showing bone enlargement, moderate to deep
scalloping and interruption of the cortex with invasion of the soH tissues were
treated by wide resection. Hence, tumours showing more aggressive features
were treated more aggressively as well. This could favour curettage over wide
resection in terms of local recurrence.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Unclear risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Donati 2010  (Continued)
Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
28
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Donati 2010  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: Brazil
Setting: single-centre; hospital; date unknown
Participants Total participants: original article n = 23. After exclusion n = 16 (resection n = 5; intralesional n = 11)
Loss to follow-up: unknown causes
Age mean (range): unknown
Sex M:F: unknown
Inclusion criteria: grade I CS, confirmed by histology. Enneking stage 1A and 1B were included.
Exclusion criteria: < 24 months' follow-up
Follow-up months (range): 24-192
Interventions Resection: wide resection with or without endoprosthesis
Intralesional: curettage with or without adjuvant cauterisation and/or PMMA
Outcomes Complications, evidence of disease
Notes Individual participant data. We excluded 7 participants from this analysis since they did not meet
the inclusion criteria for this review: 2 tumours were localised in a phalanx, 1 in a metatarsal, 1 in the
scapula, 1 in the ischium and 2 were peripheral CSs
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
Unclear risk Choice of treatment is not well described, therefore we cannot judge on what
basis participants were treated by either treatment type.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Reason for loss to follow-up was not described.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Etchebehere 2005 
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Bias in selection of the re-
ported result
Low risk Although the given results have not been prespecified in all cases, the most
important parameters (oncological results and complications) were well docu-
mented.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Etchebehere 2005  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: Austria
Setting: single-centre; hospital; 1968-2006
Participants Total participants: n = 70 (wide resection n = 24, marginal n = 7, intralesional n = 39; trunk n = 17, ex-
tremity n = 53)
Loss to follow-up: not mentioned
Age mean (range): 40 (10-72)
Sex M:F: 39:31
Inclusion criteria: diagnosis of LGCS in any bone based on clinical exploration, radiography and histo-
logical evaluation
Exclusion criteria: not mentioned
Follow-up months (range): 6-317
Interventions Intralesional: curettage, high speed burring and PMMA, with or without plating
Resection: resection with or without reconstruction (prosthesis and/or allograft)
Outcomes Primary outcome: local recurrence
Secondary outcome: complications
Notes Tumours involving the hand and foot were included in the series, and cannot be excluded from the
whole cohort as it is presented in the article. We tried to contact the study authors for additional data,
which could not be obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
Unclear risk In this study, for tumours in extremities, margins were intralesional, margin-
al or wide. It is not clear on which grounds participants were treated by one of
the techniques.
Bias in classification of in-
terventions
Unclear risk See above
Funovics 2010 
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Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up, other than unrelated death, was not
documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Funovics 2010  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: Turkey
Setting: single-centre; hospital; 1995-2011
Participants Total participants: n = 30
Loss to follow-up: not mentioned
Age mean (range): 41 (16-69)
Sex M:F: 12:18
Inclusion criteria: grade I CS, confirmed by histology. Enneking stage 1A and 1B were included.
Exclusion criteria: < 24 months' follow-up
Follow-up months (range): resection 75 (24-186); intralesional 73 (26-124)
Interventions Resection: wide resection with reconstructions, including PMMA, allograft/autograft, endoprosthesis,
intramedullary nailing, or Ilizarov external fixator
Intralesional: curettage and local adjuvant, PMMA or bone autograft/allograft. 2 participants had
hardware stabilisation
Outcomes Primary outcome: local recurrence, metastases and/or upgrading of tumour
Secondary outcome: complications
Notes Aggregated data. We tried to contact the study author to obtain individual participant data but were
unsuccessful.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Gunay 2013 
Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
31
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Bias in selection of partici-
pants into the study
High risk Tumours that extended into the soH tissue (Enneking IB) or tumours that were
larger > 8 cm were all treated by wide resection. Hence, tumours showing
more aggressive features were treated more aggressively as well. This could
favour curettage over wide resection in terms of local recurrence.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Unclear risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
High risk Outcome parameters were not well pre-described.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Gunay 2013  (Continued)
 
 
Methods Study design: case series
Country: UK
Setting: single-centre; hospital; 1999-2005
Participants Total participants: n = 39
Loss to follow-up: not mentioned
Age mean (range): 55 (32-82)
Sex M:F: 10:29
Inclusion criteria: grade 0.5 and I CS, confirmed by histology
Exclusion criteria: < 36 months' follow-up; lesions breaching the bone cortex and/or associated with a
soH tissue mass
Follow-up months (range): 61 (36-104)
Interventions Intralesional: curettage and filling with PMMA
Outcomes Primary outcome: local recurrence
Secondary outcome: MSTS scores, metastases and/or upgrading of tumour and complications
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Hanna 2009 
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Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk This study included grade 0.5 tumours, which could be regarded as a more be-
nign tumour. Therefore, the number of local recurrences given in the study
might not reflect the true potential of LGCS to recur.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Hanna 2009  (Continued)
 
 
Methods Study design: case series
Country: South Korea
Setting: single-centre; hospital; 1997-2012
Participants Total participants: n = 36
losses to follow-up: not mentioned
Age mean (range): 46 (18-67)
Sex M:F: 13:23
Inclusion criteria: grade I CS, confirmed by histology
Exclusion criteria: < 24 months' follow-up; participants who underwent wide excision because of a
pathological fracture or extraosseous extension; no use of anhydrous alcohol adjuvant; history of previ-
ous surgical treatment; insufficient information from the medical record
Follow-up months (range): 62 (24-169)
Interventions Intralesional: curettage and additional burring, treatment with anhydrous alcohol, followed by filling
of the defect with bone graH or PMMA
Outcomes Primary outcome: local recurrence
Secondary outcome: metastases and/or upgrading of tumour, complications
Notes  
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Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk Tumours that showed signs of higher aggressiveness (pathological fracture
and extra-osseous extension) were excluded. This could favour intralesional
surgery as only the less aggressive tumours were analysed.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
High risk Outcome parameters were not well pre-described.
Other bias Unclear risk Not applicable
Kim 2015  (Continued)
 
 
Methods Study design: case series
Country: South Korea
Setting: single-centre; hospital; 2004-2013
Participants Total participants: n = 24
losses to follow-up: not mentioned
Age mean (range): 45 (18-62)
Sex M:F: 9:15
Inclusion criteria: grade I CS, confirmed by histology. Principal indication for surgery was an endosteal
erosion and tumour > 6 cm in longitudinal length
Exclusion criteria: < 48 months' follow-up; ACT not in a long bone; escalated histological grade after
definitive surgery; separated lesion that was not included within the range of curettage. 1 case was
treated conservatively. In the event of extraosseous soH-tissue extension, the tumour was resected.
Follow-up months (interquartile range): 66 (50-84)
Interventions Intralesional: curettage and additional burring, treatment with hydrogen peroxide and saline rinsing,
followed by filling of the defect with bone graH or PMMA. In 16 participants, prophylactic hardware was
used.
Outcomes Primary outcome: local recurrence
Kim 2018 
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Secondary outcome: metastases and/or upgrading of tumour, complications, MSTS scores
Notes The data presented in this paper are from a different institute than Kim 2015.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk Only stage 1A tumours were treated by curettage, which could favour local re-
currence rates.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk There was no loss to follow-up.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Kim 2018  (Continued)
 
 
Methods Study design: retrospective cohort study
Country: USA
Setting: single-centre; hospital; 1980-2001
Participants Total participants: 70 (intralesional n = 13, wide resection n = 57)
Loss to follow-up: not mentioned
Age mean (SD): 37 ± 19.3 (intralesional) 43 ± 18.4 (wide resection)
Sex M:F: 1:1.6
Inclusion criteria: intramedullary lesion of the appendicular extremity with definite histologic diagno-
sis of LGCS
Exclusion criteria: variants of CS, including secondary peripheral CS, dedifferentiated CS, soH tissue
CS, clear cell CS, synovial CS, and mesenchymal CS. Moreover, participants with tumours in the axial
skeleton, pelvis, spine, foot, and hand were excluded. Grade 0.5 and borderline CS also excluded
Follow-up months (range): 91 (4-274)
Interventions Intralesional: curettage with phenolisation and bone graH or PMMA
Leerapun 2007 
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Wide resection: not further specified
Outcomes Primary outcome: disease-free survival
Secondary outcome: local recurrences, metastases, death due to disease
Notes The follow-up interval (see methods section, minimum 2 years) was insufficient, and individual partic-
ipant data were not available for extraction. We tried to contact the study author to obtain individual
participant data but were unsuccessful.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk In the group of participants treated by resection, there were more with corti-
cal disruption and soH tissue extension. Hence, tumours showing more aggres-
sive features were treated more aggressively as well. This could favour curet-
tage over wide resection in terms of local recurrence.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias High risk Groups were not controlled for experience of the surgeon and pre-operative
functioning level of the participants.
Leerapun 2007  (Continued)
 
 
Methods Study design: case series
Country: Turkey
Setting: single-centre; hospital; 2007-2012
Participants Total participants: n = 21
Loss to follow-up: not mentioned
Age mean (range): 49 (18-71)
Sex M:F: 7:14
Inclusion criteria: Grade I CS, confirmed by histology
Mermerkaya 2014 
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Exclusion criteria: < 24 months' follow-up; lesions breaching the bone cortex and/or associated with a
soH tissue mass
Follow-up months (range): 58.4 (24-85)
Interventions Intralesional: curettage followed by application of high-speed burring, thermal cauterisation and PM-
MA
Outcomes Primary outcome: local recurrence
Secondary outcome: complications, MSTS scores
Notes It was not possible to extract the data needed from the presented data.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk Tumours that showed signs of higher aggressiveness (breaching the bone cor-
tex and/or associated with a soH tissue mass) were excluded. This could favour
intralesional surgery as only the less aggressive tumours were analysed.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Mermerkaya 2014  (Continued)
 
 
Methods Study design: case series
Country: USA
Setting: single-centre; hospital; 1997-2008
Participants Total participants: original article n = 46. After exclusion n = 22
Loss to follow-up: not mentioned
Age mean (range): 51.1 (37-73)
Sex M:F: 7:15
Mohler 2010 
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Inclusion criteria: enchondroma, grade 0.5 and I CS, assessed by clinical, radiological and histological
results
Exclusion criteria: < 18 months' follow-up
Follow-up months (range): 59.8 (28-134)
Interventions Intralesional: curettage and 3 cycles of liquid nitrogen application with burr drilling followed by ce-
mentation of the defect and internal fixation to prevent pathologic fracture
Outcomes Primary outcome: local recurrence
Secondary outcome: complications, MSTS scores
Notes We excluded 24 participants from this case series since they did not meet the inclusion criteria for this
review: enchondroma (n = 16) and/or follow-up too short (n = 6) and/or axial skeleton tumour (n = 2)
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
High risk Although we were able to exclude data of participants with enchondroma,
grade 0.5 tumours were also included. Therefore, the number of local recur-
rences given in the study might not reflect the true potential of CS1 to recur.
Bias in classification of in-
terventions
High risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data High risk Number of participants lost to follow-up was not documented.
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Mohler 2010  (Continued)
 
 
Methods Study design: case series
Country: the Netherlands
Setting: single-centre; hospital; 1994-2003
Participants Total participants: 123 (130 tumours); active enchondroma n = 18, aggressive enchondroma n = 57,
LGCS n = 55
Loss to follow-up: 1
Van der Geest 2008 
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Age mean (range): 49 (13-83)
Sex M:F: not mentioned
Inclusion criteria: surgical treatment was performed in case of invalidating pain, scalloping of the cor-
tex of the involved bone or suspected low-grade malignancy after biopsy. Lesions with a clinical and ra-
diologic latent appearance were followed periodically and only treated in case of transformation to ag-
gressive behaviour.
Exclusion criteria: none mentioned
Follow-up months (range): 60 (24-144) for LGCS
Interventions Intralesional: curettage, cryosurgery, filling of the cavity with homologous or autologous bone chips
or PMMA (3 cases). Preventive plating if necessary
Outcomes Primary outcome: local recurrence
Secondary outcome: secondary operations, complications, functional outcome by means of the MSTS
Notes Localisation of tumour not specified, data extraction not possible. Although MSTS scores were ob-
tained, only differences in scores between subgroups were calculated. The scores themselves were not
documented. We contacted the study authors, but were not able to obtain individual MSTS scores.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
Unclear risk The methods section suggests that only stage 1A tumours were treated, but
this is not fully documented. Moreover, exclusion criteria were not mentioned.
So, it is not clear whether this study group reflects the spectrum of LGCS.
Bias in classification of in-
terventions
Unclear risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk Loss to follow-up well documented, not likely to influence outcome rates
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Most outcomes were not fully defined in the methods section, however all rele-
vant outcome parameters according to the literature were reported.
Other bias Unclear risk Not applicable
Van der Geest 2008  (Continued)
 
 
Methods Study design: case series
Country: the Netherlands
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Setting: single-centre; hospital; 1994-2005
Participants Total participants: 85
Loss to follow-up: 5
Age mean (range): 47 (15-72)
Sex M:F: not mentioned
Inclusion criteria: likely presence of LGCS located in 1 of the long bones on the Gd-MRI scan
Exclusion criteria: none mentioned
Follow-up months (range): 82 (2-169)
Interventions Intralesional: curettage, phenolisation and allograft bone chips
Outcomes Primary outcome: local recurrence
Secondary outcome: secondary operations, complications
Notes Minimal follow-up was insufficient (4 months) and participants with limited follow-up could not be ex-
cluded from analysis because data were presented in aggregated form. We attempted to contact the
study authors for additional data, which could not be obtained. Only 5 participants had follow-up < 2
years.
Risk of bias
Bias Authors' judgement Support for judgement
Bias due to confounding High risk Study authors did not use an appropriate analysis method that adjusted for all
the important confounding domains and for time-varying confounding.
Bias in selection of partici-
pants into the study
Unclear risk The methods section suggests that only stage 1A tumours were treated, but
this is not fully documented. Moreover, exclusion criteria were not mentioned.
So, it is not clear whether this study group reflects the spectrum of LGCS.
Bias in classification of in-
terventions
Unclear risk See above
Bias due to deviations
from intended interven-
tions
Unclear risk Post-operative rehabilitation was not documented.
Bias due to missing data Low risk Loss to follow-up well documented, not likely to influence outcome rates
Bias in measurement of
outcomes
Low risk Blinding of participants, assessors or personnel was not applied, however we
judged that the occurrence of events was unrelated to blinding.
Bias in selection of the re-
ported result
Low risk Inclusion criteria were well described, the pre-specified outcomes were all re-
ported.
Other bias Unclear risk Not applicable
Verdegaal 2012  (Continued)
ACT: atypical cartilaginous tumour; CS: chondrosarcoma; Gd-MRI: gadolinium-magnetic resonance imaging; LGCS: low-grade
chondrosarcoma; MSTS: Musculoskeletal Tumor Society; PMMA: polymethyl methacrylate
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahlmann 2007 Case series, sample size too small (< 20); n = 10
Errani 2017 35 participants with LGCS were treated by curettage. 33 were in the long bones, 2 were in the calca-
neus. After excluding participants with a follow-up < 24 months, with enchondroma and/or with a
tumour not in the long bones (e.g. calcaneus), only 12 participants treated by curettage remained,
which was too small as a case series.
Lee 1999 86 participants with LGCS (central and exostotic) were treated by (marginal) resection or intrale-
sional treatment, survival for LGCS localised in the extremities was not fully documented, and
could therefore not be included in the meta-analysis or narrative summary. We attempted to con-
tact the study authors for individual participant data with tumours in the long bones, which could
not be obtained
Okada 2009 Insufficient number of cases (2) to include as a case series
Ozaki 1996 Data extraction shows that were only 3 participants with long bone LGCS included. All other tu-
mours were of higher grade, or localised in the axial skeleton or pelvis.
Puri 2009 Insufficient number of cases (11 LGCS) to include as a case series
Schreuder 1998 Study analyses a total of 23 cases, however only 9 with a final diagnosis of LGCS. Of those 9 cases,
only 3 cases have a minimum follow-up of 24 months.
Souna 2010 Insufficient number of cases (15) meeting the inclusion criteria to include as a case series
LGCS: low-grade chondrosarcoma; MSTS: Musculoskeletal Tumor Society
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Methods Study design: case series
Country: Germany
Setting: single-centre; hospital; 1982-2004
Participants Total participants: n = 115 (LGCS n = 56)
Loss to follow-up: none
Age mean (range): 47 (14-79)
Sex M:F: 1.56:1
Inclusion criteria: primary central chondrosarcoma (all grades)
Exclusion criteria: participants treated with palliative intent or with follow-up of < 5 years after di-
agnosis
Follow-up years (range): mean follow-up period for survivors was 12 (5-24) years
Interventions Only margins mentioned (intralesional, marginal, wide and radical)
Outcomes Overall survival (%) at 5 and 10 years
Andreou 2011 
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Notes 56 participants were treated for LGCS in the axial skeleton and extremities, with recurrence-free
survival of 73% and 68% at 5 and 10 years respectively. Survival for LGCS localised in the extrem-
ities was not fully documented since data of extremity LGCS and axial skeleton LGCS was mixed,
and could therefore not be included in the meta-analysis or narrative summary. We attempted to
contact the study authors for individual participant data with tumours in the long bones, which
could not be obtained.
Andreou 2011  (Continued)
 
 
Methods Study design: case series
Country: Italy
Setting: single-centre; hospital; 1990-2008
Participants Total participants: n = 296 (LGCS; n = 87)
Loss to follow-up: none
Age mean (range): 50 (13-88)
Sex M:F: not mentioned
Inclusion criteria: primary conventional central CS (all grades)
Exclusion criteria: incomplete documentation on clinical characteristics, treatment and outcome
Follow-up years (range): 7 (1.6-19.8)
Interventions For LGCS: intralesional (38%), resection (59%) and amputation (3%)
Outcomes Overall survival (%) at 5, 10, and 15 years
Notes 87 participants with LGCS were treated and showed recurrence-free survival for local recurrence of
90% and 88% at 5 and 10 years respectively and 99% and 5 and 10 years for metastases. They did
not find a statistical difference between participants treated by intralesional treatment versus wide
resection, or between extremities or trunk site tumours. However, survival for LGCS localised in the
extremities was not fully documented, and could therefore not be included in the meta-analysis or
narrative summary. We attempted to contact the study authors for individual participant data with
tumours in the long bones, which could not be obtained.
Angelini 2012 
 
 
Methods Study design: case series
Country: Brazil
Setting: single-centre; hospital; 1986-2006
Participants Total participants: n = 46 (LGCS n = 23)
Loss to follow-up: none
Age mean (range): 43.6 (18-79) for LGCS
Sex M:F: 1:1.9
de Camargo 2010 
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Inclusion criteria: primary conventional central chondrosarcoma (grade 1 and 2)
Exclusion criteria: secondary, mesenchymal, dedifferentiated periosteal and grade 3 CSs. Fol-
low-up of < 30 months for living participants
Follow-up months (range): 99 (32-312)
Interventions For LGCS: intralesional (n = 19) and wide resection (n = 3)
Outcomes Overall survival rates, local recurrence rates
Notes This study included 23 participants with LGCS, with 22 in the appendicular skeleton. Of those, 19
participants were treated by intralesional treatment, and 3 by wide resection. In total, 6 local recur-
rences occurred. However, it is not specified which tumours involved the long bones (tumours in
hand, feet and shoulder girdle were included as well) and it is not specified in which participants
the local recurrences occurred. We attempted to contact the study authors for individual partici-
pant data with tumours in the long bones, which could not be obtained.
de Camargo 2010  (Continued)
 
 
Methods Study design: case series
Country: China
Setting: single-centre; hospital; 1996-2007
Participants Total participants: n = 66 (LGCS; n = 22)
Loss to follow-up: not mentioned
Age mean (range): 45 (10-79) for LGCS
Sex M:F: 4.1:1
Inclusion criteria: primary conventional central CS (grades I and II)
Exclusion criteria: clear cell, mesenchymal or extraskeletal myxoid CS; CSs diagnosed as border-
line grade I/II; and cases with recurrence of CS or a surgical history in another hospital
Follow-up months (range): 24.8 (4-131)
Interventions For LGCS: intralesional (n = 18), wide resection (n = 3) and radical (n = 1)
Outcomes Local recurrence-free survival rate
Notes The follow-up interval was insufficient in some participants, and individual participant data were
not available for extraction because the outcomes were presented as aggregated data. Further-
more, hand tumours were also included in the series. Moreover, there are remarkable differences
in local recurrence rates as presented in the table (72%) versus the body text (60%), which raises
some concerns over the consistency of the work. We attempted to contact the authors for individ-
ual participant data with tumours in the long bones, which could not be obtained.
Ma 2009 
 
 
Methods Study design: case series
Country: USA
MeMah 2013 
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Setting: single-centre; hospital; 1983-2006
Participants Total participants: n = 42 (43 lesions)
Loss to follow-up: 3
Age mean (range): 44.9 (21.8-66.4)
Sex M:F: 1:2.2
Inclusion criteria: LGCS treated with intralesional curettage and cryosurgery
Exclusion criteria: < 5 years of follow-up
Follow-up years (range): 10.2 (5-22.5)
Interventions Curettage with adjuvant cryosurgery, of which 2 different types were applied: a modified Marcove
direct-pour technique (n = 32) and a technique with closed-circuit cryoprobes (n = 11)
Outcomes Local or distant tumour recurrence, complications and functional outcome (MSTS scores)
Notes 43 tumours in 42 participants with LGCS in trunk and extremities were treated by intralesional
surgery with adjuvant cryosurgery. After minimal 5 years' follow-up, there were 4 local recurrences
(4 participants, 9.3%), all of which involved lesions that had had soH-tissue involvement at the time
of presentation. No secondary recurrences or metastases developed during follow-up. Survival for
LGCS localised in the extremities was not fully documented, and could therefore not be included in
the meta-analysis or narrative summary. We attempted to contact the study authors for individual
participant data with tumours in the long bones, which could not be obtained.
MeMah 2013  (Continued)
 
 
Methods Study design: case series
Country: Germany
Setting: single-centre; hospital; 1972-2004
Participants Total participants: n = 80 (primary lesions n = 69)
Loss to follow-up: not mentioned
Age mean (range): 45.4 (16-80)
Sex M:F: 1:1.05
Inclusion criteria: LGCS of the bone in axial skeleton and extremities
Exclusion criteria: not mentioned
Follow-up months (range): 78.5 (2-365)
Interventions Only margins mentioned: intralesional (with or without PMMA), marginal, wide and radical
Outcomes Local recurrence; switch of tumour grading; metastases; second local recurrence; death of disease
Notes 80 participants were treated for LGCS (both primary and secondary tumours in pelvis or extremi-
ties) by surgical margins ranging from intralesional to wide resection. During follow-up, 17.5% of
participants developed a local recurrence, of whom 3 participants (21%) showed upgrading of tu-
mour. Metastatic disease developed in 4 participants (4.9%), of whom 3 died of disease. This study
included a heterogeneous group of participants with LGCS, and data of LGCS localised in the ex-
Streitbuerger 2009 
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tremities was not fully documented, and could therefore not be included in the meta-analysis or
narrative summary. We attempted to contact the study authors for individual participant data with
tumours in the long bones, which could not be obtained.
Streitbuerger 2009  (Continued)
CS: chondrosarcoma; LGCS: low grade chondrosarcoma; MSTS: Musculoskeletal Tumor Society; PMMA: polymethyl methacrylate
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   outcome comparative studies
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence-free survival 7 238 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.04]
2 Function by MSTS score 3 72 Mean Difference (IV, Random, 95% CI) 12.69 [2.82, 22.55]
3 Complications 6 203 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.10, 0.55]
 
 
Analysis 1.1.   Comparison 1 outcome comparative studies, Outcome 1 Recurrence-free survival.
Study or subgroup intralesional resection Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Aarons 2009 16/17 14/16 7.76% 1.08[0.86,1.34]
Bauer 1995 20/21 14/14 17.39% 0.96[0.83,1.12]
Campanacci 2013 62/64 21/21 58.5% 0.98[0.91,1.07]
Chen 2017 4/5 3/3 1.07% 0.86[0.47,1.55]
Donati 2010 13/15 16/16 7.32% 0.87[0.69,1.09]
Etchebehere 2005 11/11 5/5 5.21% 1[0.76,1.31]
Gunay 2013 10/13 14/17 2.74% 0.93[0.65,1.35]
   
Total (95% CI) 146 92 100% 0.98[0.92,1.04]
Total events: 136 (intralesional), 87 (resection)  
Heterogeneity: Tau2=0; Chi2=2.21, df=6(P=0.9); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
Favours resection 20.5 1.50.7 1 Favours intralesional
 
 
Analysis 1.2.   Comparison 1 outcome comparative studies, Outcome 2 Function by MSTS score.
Study or subgroup intralesional resection Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Aarons 2009 17 98.2 (2.8) 16 80 (18.3) 31.39% 18.2[9.13,27.27]
Chen 2017 3 98.6 (3.1) 5 94.3 (5.1) 37.41% 4.3[-1.38,9.98]
Donati 2010 15 89.3 (11.1) 16 72.1 (14.8) 31.2% 17.2[8.03,26.37]
   
Favours resection 10050-100 -50 0 Favours intralesional
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Study or subgroup intralesional resection Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Total *** 35   37   100% 12.69[2.82,22.55]
Heterogeneity: Tau2=59.33; Chi2=9.37, df=2(P=0.01); I2=78.66%  
Test for overall effect: Z=2.52(P=0.01)  
Favours resection 10050-100 -50 0 Favours intralesional
 
 
Analysis 1.3.   Comparison 1 outcome comparative studies, Outcome 3 Complications.
Study or subgroup intralesional resection Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Aarons 2009 1/17 6/16 17.64% 0.16[0.02,1.16]
Campanacci 2013 1/64 6/21 16.71% 0.05[0.01,0.43]
Chen 2017 0/5 2/3 9.3% 0.13[0.01,2.11]
Donati 2010 0/15 0/16   Not estimable
Etchebehere 2005 3/11 3/5 49.08% 0.45[0.14,1.51]
Gunay 2013 0/13 1/17 7.26% 0.43[0.02,9.74]
   
Total (95% CI) 125 78 100% 0.23[0.1,0.55]
Total events: 5 (intralesional), 18 (resection)  
Heterogeneity: Tau2=0; Chi2=3.9, df=4(P=0.42); I2=0%  
Test for overall effect: Z=3.37(P=0)  
Favours intralesional 2000.005 100.1 1 Favours resection
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Chondrosarcoma] explode all trees
#2 chondrosarcoma*
#3 MeSH descriptor: [Chondroma] explode all trees
#4 enchondroma* or chondroma*
#5 #1 or #2 or #3 or #4
#6 intra-lesion* or intralesion*
#7 MeSH descriptor: [Curettage] explode all trees
#8 curettage
#9 phenol* or ethanol or bone cement
#10 MeSH descriptor: [Cryotherapy] explode all trees
#11 cryotherapy
#12 #6 or #7 or #8 or #9 or #10 or #11
#13 Any MeSH descriptor with qualifier(s): [Surgery - SU]
#14 MeSH descriptor: [Amputation] this term only
#15 resect* or surgery or amputat*
#16 #13 or #14 or #15
#17 #5 and #12 and #16
Appendix 2. MEDLINE search strategy
1 exp Chondrosarcoma/
2 chondrosarcoma*.mp.
3 exp Chondroma/
4 (enchondroma* or chondroma*).mp.
5 1 or 2 or 3 or 4
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6 (intra-lesion* or intralesion*).mp.
7 exp Curettage/
8 curettage.mp.
9 (phenol* or ethanol or bone cement).mp.
10 Cryotherapy/
11 cryotherapy.mp.
12 6 or 7 or 8 or 9 or 10 or 11
13 surgery.fs.
14 Amputation/
15 (resect* or surgery or amputat*).mp.
16 13 or 14 or 15
17 5 and 12 and 16
key:
[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
Appendix 3. Embase search strategy
1 chondrosarcoma/
2 chondrosarcoma*.mp.
3 chondroma/
4 (enchondroma* or chondroma*).mp.
5 1 or 2 or 3 or 4
6 (intra-lesion* or intralesion*).mp.
7 curettage/
8 curettage.mp.
9 (phenol* or ethanol or bone cement).mp.
10 exp cryotherapy/
11 cryotherapy.mp.
12 6 or 7 or 8 or 9 or 10 or 11
13 su.fs.
14 exp amputation/
15 (resect* or surgery or amputat*).mp.
16 13 or 14 or 15
17 5 and 12 and 16
mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade
name, keyword
fs=floating subheading
W H A T ' S   N E W
 
Date Event Description
15 April 2019 Amended Typographical error corrected.
 
C O N T R I B U T I O N S   O F   A U T H O R S
• EFD: designing search protocol, reviewing articles, collecting and analysing data, preparing manuscript• KG: reviewing articles, collecting and analysing data, preparing manuscript. KG collected data from Dierselhuis 2016 independently
from the database presented by the study authors.• PCJ: designing search protocol, reviewing articles, collecting and analysing data, preparing manuscript• MS: supervising manuscript, arbiter
D E C L A R A T I O N S   O F   I N T E R E S T
• ED: none known.• KG: none known.
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• MS: none known..• PJ: none known.
ED, MS and PJ are authors of the included study Dierselhuis 2016.
S O U R C E S   O F   S U P P O R T
Internal sources• None, Other.
External sources• None, Other.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We did not, as stated in the protocol, perform sensitivity analyses excluding studies at high risk of bias. For time-to-event data we were
unable to use hazard ratios as we were only able to compute risk ratios and odds ratios. We judged risk of bias according to ROBINS-I
criteria, since all series were retrospective studies. In addition to the meta-analyses, we also performed a narrative summary, either when
case series only presented data from one treatment type, or when full outcome data were not available but were still of value for this
review. KG was added to the author team during the review process.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Bone Neoplasms  [mortality]  [pathology]  [*surgery];  Chondrosarcoma  [mortality]  [pathology]  [*surgery];  Curettage  [adverse eKects]
 [*methods];  Disease-Free Survival;  Kaplan-Meier Estimate;  Neoplasm Grading;  Neoplasm Recurrence, Local;  Retrospective Studies
MeSH check words
Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Young Adult
Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
48
